{
  "ticker": "TECH",
  "content": "**Report Generated:** January 23, 2026  \n**Next Refresh:** April 24, 2026\n\n**Disclaimer:** This sell-side report was generated using Claude Sonnet 4 (claude-sonnet-4-20250514). Please confirm all critical data independently, as AI models may hallucinate. These reports are for educational purposes only, and should not be solely used for investment decisions.\n\n---\n\n# 1. Company Overview (TECH) - Comprehensive Analysis Report\n\n## 1. Company Overview\n\nBio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Its products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Spatial Biology segments. The company was founded in 1976 and is headquartered in Minneapolis, MN. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.\n\nBased in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.\n\n## 2. Current Market Data\n\nThe current price of TECH is 69.55 USD — it has decreased by −1.84% in the past 24 hours. Today Bio-Techne Corp has the market capitalization of ‪10.70 B‬, it has increased by 1.96% over the last week. Bio-Techne Corp dividend yield was 0.62% in 2025, and payout ratio reached 69.67%. The year before the numbers were 0.45% and 30.61% correspondingly.\n\nThe 52-week high for Bio-Techne Corp Stock is $79.28 and the 52-week low is $46.01. As of Jan 20, 2026, the company has ‪3.1 K‬ employees.\n\n## 3. Existing Products/Services\n\nThe protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products.\n\n**Protein Sciences Segment (~75% of revenue):**\n- The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions.\n- Cytokines and growth factors\n- Antibodies and immunoassays\n- Analytical instruments including the Maurice system\n- Wilson Wolf G-Rex® bioreactor, ProPak GMP Reagents\n\n**Diagnostics and Spatial Biology Segment (~25% of revenue):**\n- The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products.\n- RNAscope, COMET Multiomic Spatial Biology Platform\n- Diagnostic controls and calibrators\n- Spatial biology products\n\n## 4. Planned Products/Services/Projects\n\nCollectively these Innovations Strengthen each Strategic Growth Vector: Leo Next-generation, high-throughput, fully automated Western Blot system, Pipeline of hyperactive, patentable, proteins and antibodies, Multiomic (RNA and protein) visualization capabilities on COMET Leo Instrument, AI Designed Reagents, Multiomic Spatial Biology Platform\n\n- **Leo System Enhancement**: Bio-Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis\n- **AI-Designed Products**: Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio\n- **3D Multiomics Technology**: Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology\n\n## 5. Growth Strategy\n\nThe Protein Sciences segment, which accounts for 72% of net sales, remains a cash cow, delivering a 42.6% operating margin in 2025. Meanwhile, the Diagnostics and Spatial Biology segment, though smaller, has shown resilience, with a 32.0% adjusted operating margin in Q4 2025 despite a 1% year-over-year sales decline.\n\n**Key Strategic Growth Pillars:**\n- Among our growth pillars, ProteinSimple's analytical solutions extended its growth momentum and Spatial Biology stabilized while showing early signs of accelerating growth going forward.\n- In Cell Therapy, we are very excited that a few of our largest customers received Fast Track Designation by the FDA, enabling shortened clinical development and approval timelines.\n- Bio-Techne's 2026 guidance—low single-digit revenue growth and 100 basis points of operating margin expansion—may seem modest, but it's a realistic roadmap given the current environment. The company's pipeline of strategic acquisitions, including the pending Wilson Wolf deal, and its emphasis on organoid solutions and GMP reagents position it to benefit from the FDA's push to reduce animal testing in drug development.\n\n## 6. Current and Potential Major Clients\n\n**Academic and Research Institutions:**\n- Universities and research centers globally\n- NIH-funded research programs\n\n**Biopharmaceutical Companies:**\n- Few of our largest customers received Fast Track Designation by the FDA\n- Cell and gene therapy manufacturers\n- Roche is using this technology in three clinical studies and has offered support for the technology by hosting webinars with our staff.\n\n**Diagnostic Laboratories:**\n- CLIA-certified laboratories\n- Clinical diagnostic facilities\n\n## 7. Financial Data & Performance\n\n**Q1 FY2026 Performance (ended Sept 30, 2025):**\n- First quarter reported and organic revenue decreased 1% to $286.6 million.\n- GAAP earnings per share (EPS) was $0.24 versus $0.21 for first quarter 2025.\n- Delivered adjusted EPS of $0.42 compared to $0.42 for first quarter 2025.\n- Adjusted gross margin of 70.2% Adjusted operating margin of 29.9%\n- Ongoing productivity and cost containment initiatives led to 29.9% adjusted operating margin, an increase of 90 basis points compared to the prior year period.\n\n**Annual Performance:**\n- In 2025, Bio-Techne's revenue was $1.22 billion, an increase of 5.23% compared to the previous year's $1.16 billion.\n- Bio-Techne Corp EBITDA is ‪372.49 M‬ USD, and current EBITDA margin is 29.75%.\n\n## 8. Headwinds & Tailwinds\n\n**Headwinds:**\n- Persistent market headwinds, including biotech funding pressures, NIH budget uncertainty, and lingering tariff concerns. While biotech funding remains down approximately 19% year to date through October\n- However, these advancements have resulted in short- and intermediate-term order timing headwinds for our GMP proteins business.\n- Bio-Techne's long-term strategy relies on acquisitions, and the company may have difficulty finding suitable targets because of high valuations or scarcity. Additionally, it may fail to successfully integrate and scale up an acquired business.\n\n**Tailwinds:**\n- Recent data points suggest improving end market clarity. industry reports show a 6% sequential increase in our Q1 and October making the strongest funding month of calendar 2025.\n- Combined with recent large pharma pricing and onshoring agreements with the US administration, we anticipate improving conditions for biopharma.\n- On the NIH front, September outlays rose 8% year over year, closing the government's fiscal year on a strong note. While the current government shutdown clouds visibility into the fiscal year 2026 budget, both Senate and House appropriation bills suggest a flat NIH budget year over year.\n- Ongoing development and commercialization of breakthroughs in cancer, diabetes, neurodegenerative, autoimmune, and rare diseases—transforming diagnosis and care for millions worldwide. An estimated 40% reduction in Scope 1 and 2 emissions enterprise-wide\n\n## 9. Market Shares\n\nBio-Techne is a market leader in proteins, immunoassays, clinical diagnostic controls, and other reagents that are crucial for the academic, biopharmaceutical, and diagnostic markets. While specific market share percentages aren't disclosed, the company holds strong positions in:\n\n- **Life Sciences Tools Market**: The Technology sector has a total of 767 stocks, with a combined market cap of $26.07 trillion, total revenue of $3.55 trillion\n- **Biotechnology Market**: The Biotechnology Market is expected to reach USD 2.15 trillion in 2025 and grow at a CAGR of 12.90% to reach USD 3.93 trillion by 2030.\n\n## 10. Comparison to Competitors\n\n**Key Competitors:**\n- Bio-Rad Laboratories, BioLegend, Origene, Qiagen, and Merck are some of the 22 competitors of Bio-Techne.\n- Its top competitors include companies like Illumina, Landis+Gyr and Biocare Medical.\n\n**Competitive Advantages:**\n- The firm's reputation for excellent proteomic reagents and instruments allows it to generate high profit margins and strong cash flow.\n- Superior operating margins compared to many peers\n- Strong cash generation capabilities\n- Diversified global presence\n\n## 11. Partnerships, Mergers and Acquisitions\n\n**Recent Partnerships (2025):**\n- Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards\n- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology.\n- This partnership follows Bio-Techne's participation in Spear Bio's $45 million Series A funding round in 2024.\n\n**Recent Divestitures:**\n- Completed the divestiture of the Exosome Diagnostics business including the ExoDx Prostate test (EPI)\n- On August 5, 2025 mdxhealth signed a definitive agreement to acquire the Exosome Diagnostics, Inc. business from Bio-Techne, including the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory and related assets.\n\n**Acquisition History:**\n- Bio-Techne has completed 18 acquisitions so far, with an average acquisition amount of $148M. Bio-Techne's most recent acquisition is Lunaphore, a Developer of microfluidic-based instruments for tumor analysis, acquired in June 2023.\n\n## 12. Recent Developments\n\n**November 2025:**\n- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2025.\n- Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio\n\n**December 2025:**\n- Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology\n- Bio-Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis\n\n**Upcoming Events:**\n- Bio‑Techne's Q2 FY2026 earnings call on February 4, 2026\n\n## 13. AI Investment Rating & Fair Value Assessment\n\n**Analyst Consensus:**\n- According to 14 analysts, the average rating for TECH stock is \"Strong Buy.\" The 12-month stock price target is $71.23, which is an increase of 22.28% from the latest price.\n- Based on analyst ratings, Bio-Techne's 12-month average price target is 67.38. Bio-Techne has 15.63% upside potential, based on the analysts' average price target.\n- The 12 analysts that cover Bio-Techne stock have a consensus rating of \"Buy\" and an average price target of $70.58, which forecasts a 18.09% increase in the stock price over the next year.\n\n**Current Valuation Metrics:**\n- TECH is trading at a 455% premium.\n- Today Bio-Techne Corp has the market capitalization of ‪10.70 B‬\n- Current P/E and other fundamental ratios suggest premium valuation\n\n**Investment Recommendation:**\n\n**Buy Rating: 7.5/10**\n\n**Rationale:**\n1. **Strong Fundamentals**: High-margin business with 29.9% adjusted operating margin and strong cash generation\n2. **Market Leadership**: Dominant position in critical life sciences tools and reagents\n3. **Growth Catalysts**: FDA Fast Track designations for key customers, improving biotech funding environment, strategic partnerships\n4. **Innovation Pipeline**: Strong R&D focus with AI-designed reagents and advanced analytical platforms\n5. **Analyst Support**: Strong Buy consensus with average price target suggesting 15-22% upside\n\n**Risk Factors:**\n- Premium valuation leaves little room for error\n- Dependence on biotech funding cycles\n- Acquisition integration risks\n- NIH budget uncertainties\n\n**Estimated Fair Value: $74.00**\n\nThis represents approximately 6% upside from current levels and accounts for:\n- Premium multiple justified by market leadership and margins\n- Conservative growth assumptions given market headwinds\n- Strong balance sheet and cash generation capabilities\n- Strategic positioning in growing life sciences markets\n\nThe stock appears suitable for growth-oriented investors with moderate risk tolerance, particularly given the improving biotech funding environment and the company's strong competitive position in essential life sciences tools.",
  "generated_date": "2026-01-23T08:38:51.860998",
  "next_refresh_date": "2026-04-24T08:38:51.860998",
  "model": "claude-sonnet-4-20250514",
  "cost": 0.39755535000000003,
  "tokens": {
    "input": 195,
    "output": 4929,
    "cache_creation": 66321,
    "cache_read": 247772
  },
  "tldr_summary": "Bio-Techne Corp is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities, operating through protein sciences and diagnostics segments. \n\nThe company is a market leader in protein reagents and diagnostic tools, with strong positioning in academic, pharmaceutical, and diagnostic markets. Its protein sciences segment generates 75% of revenue with impressive 42.6% operating margins, while the diagnostics segment shows resilience. Key growth strategies include expanding spatial biology technologies, AI-designed reagents, and strategic partnerships, with recent developments like licensing AI-designed molecules and advancing 3D multiomics technology. Competitive advantages include superior operating margins, strong cash generation, and a diversified global presence. Notable tailwinds include improving biotech funding and potential growth in cell and gene therapies.\n\nThe AI analysis provides a \"Buy\" rating of 7.5/10, with a fair value estimate of $74.00, representing approximately 6% upside and reflecting the company's strong market leadership and innovative potential."
}